Metamizol Hcs (Metamizole Sodium Monohydrate)

Metamizole sodium works by non‑selectively inhibiting cyclooxygenase enzymes, which lowers prostaglandin production. This reduces peripheral pain signaling and fever. In addition, it exerts central analgesic and spasmolytic actions, although the exact mechanisms within the central nervous system are not fully understood.

The dosage of Metamizol Hcs is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and clinical response. Healthcare professionals adjust the dose according to established guidelines and individual patient factors.

Safety of Metamizol Hcs during pregnancy and lactation has not been established. It is generally avoided unless the potential benefit outweighs the possible risk to the fetus or infant, and only under close medical supervision.

To order Metamizol Hcs, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamizol Hcs belongs to the pyrazolone class, offering potent analgesic and antipyretic effects similar to strong NSAIDs but with a distinct safety profile. Unlike many NSAIDs, it has a lower risk of gastrointestinal ulceration but carries a rare risk of agranulocytosis, which must be weighed against alternatives.

Metamizol Hcs should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain its stability and sterility.

Metamizol Hcs is administered by a healthcare professional via intramuscular or intravenous injection. The route is chosen based on the clinical situation, and the injection should be performed using aseptic technique in a suitable clinical setting.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, severe skin reactions such as Stevens‑Johnson syndrome, anaphylactic shock, and hepatotoxicity. Prompt recognition of symptoms and immediate medical attention are essential if these events occur.

Metamizol Hcs should be avoided in patients with known hypersensitivity to pyrazolones, a history of blood dyscrasias, severe renal or hepatic impairment, and in individuals where the risk of agranulocytosis outweighs the therapeutic benefit. Pregnant or breastfeeding women should use it only if clearly indicated.